Mersana Therapeutics Announces Topline Data from UPLIFT
UPLIFT clinical trial did not meet its primary endpoint Company realigns focus and significantly reduces expenses to extend cash runway into 2026Conference...
Source: globenewswire.com
Garvin Yang News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Garvin Yang. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Garvin Yang Today - Breaking & Trending Today
Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer
The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.
Source: onclive.com
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to Mersana Therapeutics Fourth Quarter and Year End 2022 Conference Call and Webcast. Currently, all participants are in a listen-only mode.
Source: insidermonkey.com
Howell High School renews graduation tradition at Breslin Center
Howell High School holds its graduation back at Michigan State's Breslin Center after several years of COVID restrictions.
Source: livingstondaily.com
How to unlock additional characters in Rescue Party: Live!
Be at your most fashionable while you save people from disasters.
Source: gamepur.com